Lost at SCLC: a Review of Potential Platinum Sensitizers

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2024 Aug 23

PMID 39177894

Authors

Bryan Oronsky

Nacer Abrouk

Li Mao

Yunle Shen

Xiaohui Wang

Luyang Zhao

Scott Caroen

Tony Reid

Affiliations

Soon will be listed here.

Abstract

The expression "lost at sea" means to be confused or perplexed. By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a "recalcitrant cancer." Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.

Citing Articles

[PKM1 Regulates the Expression of Autophagy and Neuroendocrine Markers  in Small Cell Lung Cancer].

Tang C, Jin Y, Zhao P, Tian L, Li H, Yang C Zhongguo Fei Ai Za Zhi. 2024; 27(9):645-653.

PMID: 39492579 PMC: 11534549. DOI: 10.3779/j.issn.1009-3419.2024.102.33.

References

Ferrarotto R, Anderson I, Medgyasszay B, Garcia-Campelo M, Edenfield W, Feinstein T . Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Med. 2021; 10(17):5748-5756. PMC: 8419768. DOI: 10.1002/cam4.4089. View

Ganti A, Loo B, Bassetti M, Blakely C, Chiang A, DAmico T . Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(12):1441-1464. PMC: 10203822. DOI: 10.6004/jnccn.2021.0058. View

Oronsky B, Ray C, Spira A, Trepel J, Carter C, Cottrill H . A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol. 2017; 34(6):103. DOI: 10.1007/s12032-017-0960-z. View

Reid T, Oronsky B, Scicinski J, Scribner C, Knox S, Ning S . Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015; 16(9):1133-1142. DOI: 10.1016/S1470-2045(15)00089-3. View

Bonomi M, Blakaj D, Kabarriti R, Colvett K, Takiar V, Biagioli M . PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2023; 116(3):551-559. DOI: 10.1016/j.ijrobp.2022.12.031. View

Blackhall F, Girard N, Livartowski A, McDonald L, Roset M, Lara N . Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. 2023; 13(2):e052556. PMC: 9906168. DOI: 10.1136/bmjopen-2021-052556. View

Ahn M, Cho B, Felip E, Korantzis I, Ohashi K, Majem M . Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023; 389(22):2063-2075. DOI: 10.1056/NEJMoa2307980. View

Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson A . A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation. Drugs. 2023; 83(5):389-402. PMC: 10015535. DOI: 10.1007/s40265-023-01838-z. View

Gergen A, Scott C, Mitchell J . Surgery for limited stage small cell lung cancer. J Thorac Dis. 2020; 12(10):6291-6297. PMC: 7656341. DOI: 10.21037/jtd.2020.03.79. View

10.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox S, Peehl D . Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget. 2015; 6(41):43172-81. PMC: 4791224. DOI: 10.18632/oncotarget.6526. View

11.

Lissa D, Takahashi N, Desai P, Manukyan I, Schultz C, Rajapakse V . Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. Nat Commun. 2022; 13(1):2023. PMC: 9018864. DOI: 10.1038/s41467-022-29517-9. View

12.

Morgensztern D, Rose M, Waqar S, Morris J, Ma P, Reid T . RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer. 2019; 121(3):211-217. PMC: 6738071. DOI: 10.1038/s41416-019-0504-8. View

13.

Kondo R, Watanabe S, Shoji S, Ichikawa K, Abe T, Baba J . A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer. Oncology. 2018; 94(4):223-232. DOI: 10.1159/000486622. View

14.

Torres-Duran M, Curiel-Garcia M, Ruano-Ravina A, Provencio M, Parente-Lamelas I, Hernandez-Hernandez J . Small-cell lung cancer in never-smokers. ESMO Open. 2021; 6(2):100059. PMC: 7920829. DOI: 10.1016/j.esmoop.2021.100059. View

15.

Oronsky B, Reid T, Oronsky A, Carter C . What's New in SCLC? A Review. Neoplasia. 2017; 19(10):842-847. PMC: 5596356. DOI: 10.1016/j.neo.2017.07.007. View

16.

Rittberg R, Leung B, Al-Hashami Z, Ho C . Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer. Front Oncol. 2022; 12:1002385. PMC: 9520052. DOI: 10.3389/fonc.2022.1002385. View

17.

Herzog B, Devarakonda S, Govindan R . Overcoming Chemotherapy Resistance in SCLC. J Thorac Oncol. 2021; 16(12):2002-2015. DOI: 10.1016/j.jtho.2021.07.018. View

18.

Bogart J, Waqar S, Mix M . Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):661-670. PMC: 10476774. DOI: 10.1200/JCO.21.01639. View

19.

Hou J, Krebs M, Lancashire L, Sloane R, Backen A, Swain R . Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012; 30(5):525-32. DOI: 10.1200/JCO.2010.33.3716. View

20.

Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M . Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemother Pharmacol. 2017; 80(5):895-907. PMC: 5676816. DOI: 10.1007/s00280-017-3392-8. View